ATE375391T1 - Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen - Google Patents

Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen

Info

Publication number
ATE375391T1
ATE375391T1 AT00925004T AT00925004T ATE375391T1 AT E375391 T1 ATE375391 T1 AT E375391T1 AT 00925004 T AT00925004 T AT 00925004T AT 00925004 T AT00925004 T AT 00925004T AT E375391 T1 ATE375391 T1 AT E375391T1
Authority
AT
Austria
Prior art keywords
dna fragments
corresponding dna
chlamydia antigens
chlamydia
truncated
Prior art date
Application number
AT00925004T
Other languages
German (de)
English (en)
Inventor
Andrew D Murdin
Raymond P Oomen
Joe Wang
Pamela Dunn
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE375391T1 publication Critical patent/ATE375391T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00925004T 1999-05-03 2000-05-03 Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen ATE375391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13227099P 1999-05-03 1999-05-03
US14127699P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
ATE375391T1 true ATE375391T1 (de) 2007-10-15

Family

ID=26830227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00925004T ATE375391T1 (de) 1999-05-03 2000-05-03 Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen

Country Status (8)

Country Link
US (4) US20030095973A1 (https=)
EP (1) EP1177301B1 (https=)
JP (1) JP4695763B2 (https=)
AT (1) ATE375391T1 (https=)
AU (1) AU780444B2 (https=)
CA (1) CA2373021A1 (https=)
DE (1) DE60036698T2 (https=)
WO (1) WO2000066739A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1135501A1 (en) 1998-12-01 2001-09-26 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
KR20100132086A (ko) 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
JP2003512017A (ja) * 1998-12-23 2003-04-02 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000039157A1 (en) 1998-12-28 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
CA2365196C (en) 1999-03-12 2011-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2373021A1 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001036455A2 (en) * 1999-11-12 2001-05-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60044146D1 (de) * 1999-12-22 2010-05-20 Aventis Pasteur D ihre verwendungen
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
US20080112965A1 (en) * 2001-10-01 2008-05-15 Aventis Pasteur Limited Chlamydia OMP antigen
CA2754618A1 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
CA2780207A1 (en) * 2009-11-18 2011-05-26 Auburn University Low antigen-dose immunization for maximizing t-helper cell 1 (th1) immunity against disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
EP0784059B1 (en) * 1994-09-20 2009-02-11 Hitachi Chemical Co., Ltd. Polynucleotides encoding an antigenic polypeptide of chlamydia pneumoniae
FR2726764B1 (fr) * 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US5840788A (en) 1997-06-20 1998-11-24 Acushnet Company Ultraviolet light resistant urethane top coat for golf balls
DK1007685T3 (da) * 1997-06-23 2006-08-14 Loke Diagnostics Aps Overfladeeksponerede proteiner fra chlamydia pneumoniae
US7459524B1 (en) * 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
ES2352082T3 (es) 1997-11-21 2011-02-15 Merck Serono Biodevelopment Polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección polipéptido de la membrana externa de chlamydia pneumoniae, fragmentos del mismo y sus usos, en particular para el diagnóstico, la prevención y el tratamiento de una infección.
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1129202A2 (en) 1998-10-28 2001-09-05 Aventis Pasteur Limited Chlamydia antigenes and corresponding dna fragments and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
EP1135501A1 (en) 1998-12-01 2001-09-26 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
KR20100132086A (ko) 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
CA2373021A1 (en) 1999-05-03 2000-11-09 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU2138501A (en) 1999-12-22 2001-07-03 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
DE60044146D1 (de) 1999-12-22 2010-05-20 Aventis Pasteur D ihre verwendungen
US20020082402A1 (en) 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020071831A1 (en) 2000-04-04 2002-06-13 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020132994A1 (en) 2000-04-04 2002-09-19 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094965A1 (en) 2000-04-04 2002-07-18 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20030100706A1 (en) 2000-04-04 2003-05-29 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20040254130A1 (en) 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001258105A1 (en) 2000-05-08 2001-11-20 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae

Also Published As

Publication number Publication date
WO2000066739A3 (en) 2001-01-11
US20040086525A1 (en) 2004-05-06
EP1177301A2 (en) 2002-02-06
JP2002542827A (ja) 2002-12-17
US20030095973A1 (en) 2003-05-22
EP1177301B1 (en) 2007-10-10
CA2373021A1 (en) 2000-11-09
DE60036698D1 (de) 2007-11-22
US20050202048A1 (en) 2005-09-15
US20090155350A1 (en) 2009-06-18
AU780444B2 (en) 2005-03-24
US7070792B2 (en) 2006-07-04
JP4695763B2 (ja) 2011-06-08
DE60036698T2 (de) 2008-07-24
AU4388500A (en) 2000-11-17
US7658934B2 (en) 2010-02-09
US7595058B2 (en) 2009-09-29
WO2000066739A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
ATE375391T1 (de) Chlamydia-antigene und entsprechende dna- fragmente und deren verwendungen
ATE384793T1 (de) Chlamydia antigene und entsprechende dna- fragmente und ihre verwendungen
ATE463575T1 (de) Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
ATE500843T1 (de) Streptococcus pneumoniae proteine und impfstoffe
CY1118901T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE60139690D1 (de) Immunisierung gegen chlamydia pneumoniae
BR9906927A (pt) Proteìnas de neisseria meningitidis
DE60228758D1 (de) Immunisierung gegen chlamydia tracheomatis
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20033364D0 (no) Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
WO2001081380A3 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE417106T1 (de) Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
WO2001046226A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
EP2088197A3 (en) Haemophilus influenzae antigens and corresponding DNA fragments
BR0207447A (pt) Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof
WO2000006742A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
EA200100701A1 (ru) Белки наружной поверхности, их гены и их применение
DE60234772D1 (de) Gruppe-b streptococcus antigene und entsprechende dna-fragmente
WO2000011183A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1177301

Country of ref document: EP